Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against burkholderia pseudomallei

Laura A. Muruato, Daniel Tapia, Christopher L. Hatcher, Mridul Kalita, Paul J. Brett, Anthony E. Gregory, James E. Samuel, Richard W. Titball, Alfredo Torres

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Burkholderia pseudomallei is a Gram-negative, facultative intracellular pathogen that causes the disease melioidosis in humans and other mammals. Respiratory infection with B. pseudomallei leads to a fulminant and often fatal disease. It has previously been shown that glycoconjugate vaccines can provide significant protection against lethal challenge; however, the limited number of known Burkholderia antigens has slowed progress toward vaccine development. The objective of this study was to identify novel antigens and evaluate their protective capacity when incorporated into a nanoglycoconjugate vaccine platform. First, an in silico approach to identify antigens with strong predicted immunogenicity was developed. Protein candidates were screened and ranked according to predicted subcellular localization, transmembrane domains, adhesive properties, and ability to interact with major histocompatibility complex (MHC) class I and class II. From these in silico predictions, we identified seven “high priority” proteins that demonstrated seroreactivity with anti-B. pseudomallei murine sera and convalescent human melioidosis sera, providing validation of our methods. Two novel proteins, together with Hcp1, were linked to lipopolysaccharide (LPS) and incorporated with the surface of a gold nanoparticle (AuNP). Animals receiving AuNP glycoconjugate vaccines generated high protein- and polysaccharide-specific antibody titers. Importantly, immunized animals receiving the AuNP-FlgL-LPS alone or as a combination demonstrated up to 100% survival and reduced lung colonization following a lethal challenge with B. pseudomallei. Together, this study provides a rational approach to vaccine design that can be adapted for other complex pathogens and provides a rationale for further preclinical testing of AuNP glycoconjugate in animal models of infection.

Original languageEnglish (US)
Article numbere00206-17
JournalClinical and Vaccine Immunology
Volume24
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Burkholderia pseudomallei
Vaccines
Glycoconjugates
Melioidosis
Animals
Pathogens
Antigens
Computer Simulation
Lipopolysaccharides
Proteins
Burkholderia
Mammals
Major Histocompatibility Complex
Serum
Respiratory Tract Infections
Gold
Adhesives
Nanoparticles
Polysaccharides
Animal Models

Keywords

  • Burkholderia pseudomallei
  • Melioidosis
  • Nanoglycoconjugate
  • Nanovaccine
  • Reverse vaccinology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against burkholderia pseudomallei. / Muruato, Laura A.; Tapia, Daniel; Hatcher, Christopher L.; Kalita, Mridul; Brett, Paul J.; Gregory, Anthony E.; Samuel, James E.; Titball, Richard W.; Torres, Alfredo.

In: Clinical and Vaccine Immunology, Vol. 24, No. 11, e00206-17, 01.11.2017.

Research output: Contribution to journalArticle

Muruato, LA, Tapia, D, Hatcher, CL, Kalita, M, Brett, PJ, Gregory, AE, Samuel, JE, Titball, RW & Torres, A 2017, 'Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against burkholderia pseudomallei', Clinical and Vaccine Immunology, vol. 24, no. 11, e00206-17. https://doi.org/10.1128/CVI.00206-17
Muruato, Laura A. ; Tapia, Daniel ; Hatcher, Christopher L. ; Kalita, Mridul ; Brett, Paul J. ; Gregory, Anthony E. ; Samuel, James E. ; Titball, Richard W. ; Torres, Alfredo. / Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against burkholderia pseudomallei. In: Clinical and Vaccine Immunology. 2017 ; Vol. 24, No. 11.
@article{e355b57635b84158b6286f81ce5a6415,
title = "Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against burkholderia pseudomallei",
abstract = "Burkholderia pseudomallei is a Gram-negative, facultative intracellular pathogen that causes the disease melioidosis in humans and other mammals. Respiratory infection with B. pseudomallei leads to a fulminant and often fatal disease. It has previously been shown that glycoconjugate vaccines can provide significant protection against lethal challenge; however, the limited number of known Burkholderia antigens has slowed progress toward vaccine development. The objective of this study was to identify novel antigens and evaluate their protective capacity when incorporated into a nanoglycoconjugate vaccine platform. First, an in silico approach to identify antigens with strong predicted immunogenicity was developed. Protein candidates were screened and ranked according to predicted subcellular localization, transmembrane domains, adhesive properties, and ability to interact with major histocompatibility complex (MHC) class I and class II. From these in silico predictions, we identified seven “high priority” proteins that demonstrated seroreactivity with anti-B. pseudomallei murine sera and convalescent human melioidosis sera, providing validation of our methods. Two novel proteins, together with Hcp1, were linked to lipopolysaccharide (LPS) and incorporated with the surface of a gold nanoparticle (AuNP). Animals receiving AuNP glycoconjugate vaccines generated high protein- and polysaccharide-specific antibody titers. Importantly, immunized animals receiving the AuNP-FlgL-LPS alone or as a combination demonstrated up to 100{\%} survival and reduced lung colonization following a lethal challenge with B. pseudomallei. Together, this study provides a rational approach to vaccine design that can be adapted for other complex pathogens and provides a rationale for further preclinical testing of AuNP glycoconjugate in animal models of infection.",
keywords = "Burkholderia pseudomallei, Melioidosis, Nanoglycoconjugate, Nanovaccine, Reverse vaccinology",
author = "Muruato, {Laura A.} and Daniel Tapia and Hatcher, {Christopher L.} and Mridul Kalita and Brett, {Paul J.} and Gregory, {Anthony E.} and Samuel, {James E.} and Titball, {Richard W.} and Alfredo Torres",
year = "2017",
month = "11",
day = "1",
doi = "10.1128/CVI.00206-17",
language = "English (US)",
volume = "24",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against burkholderia pseudomallei

AU - Muruato, Laura A.

AU - Tapia, Daniel

AU - Hatcher, Christopher L.

AU - Kalita, Mridul

AU - Brett, Paul J.

AU - Gregory, Anthony E.

AU - Samuel, James E.

AU - Titball, Richard W.

AU - Torres, Alfredo

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Burkholderia pseudomallei is a Gram-negative, facultative intracellular pathogen that causes the disease melioidosis in humans and other mammals. Respiratory infection with B. pseudomallei leads to a fulminant and often fatal disease. It has previously been shown that glycoconjugate vaccines can provide significant protection against lethal challenge; however, the limited number of known Burkholderia antigens has slowed progress toward vaccine development. The objective of this study was to identify novel antigens and evaluate their protective capacity when incorporated into a nanoglycoconjugate vaccine platform. First, an in silico approach to identify antigens with strong predicted immunogenicity was developed. Protein candidates were screened and ranked according to predicted subcellular localization, transmembrane domains, adhesive properties, and ability to interact with major histocompatibility complex (MHC) class I and class II. From these in silico predictions, we identified seven “high priority” proteins that demonstrated seroreactivity with anti-B. pseudomallei murine sera and convalescent human melioidosis sera, providing validation of our methods. Two novel proteins, together with Hcp1, were linked to lipopolysaccharide (LPS) and incorporated with the surface of a gold nanoparticle (AuNP). Animals receiving AuNP glycoconjugate vaccines generated high protein- and polysaccharide-specific antibody titers. Importantly, immunized animals receiving the AuNP-FlgL-LPS alone or as a combination demonstrated up to 100% survival and reduced lung colonization following a lethal challenge with B. pseudomallei. Together, this study provides a rational approach to vaccine design that can be adapted for other complex pathogens and provides a rationale for further preclinical testing of AuNP glycoconjugate in animal models of infection.

AB - Burkholderia pseudomallei is a Gram-negative, facultative intracellular pathogen that causes the disease melioidosis in humans and other mammals. Respiratory infection with B. pseudomallei leads to a fulminant and often fatal disease. It has previously been shown that glycoconjugate vaccines can provide significant protection against lethal challenge; however, the limited number of known Burkholderia antigens has slowed progress toward vaccine development. The objective of this study was to identify novel antigens and evaluate their protective capacity when incorporated into a nanoglycoconjugate vaccine platform. First, an in silico approach to identify antigens with strong predicted immunogenicity was developed. Protein candidates were screened and ranked according to predicted subcellular localization, transmembrane domains, adhesive properties, and ability to interact with major histocompatibility complex (MHC) class I and class II. From these in silico predictions, we identified seven “high priority” proteins that demonstrated seroreactivity with anti-B. pseudomallei murine sera and convalescent human melioidosis sera, providing validation of our methods. Two novel proteins, together with Hcp1, were linked to lipopolysaccharide (LPS) and incorporated with the surface of a gold nanoparticle (AuNP). Animals receiving AuNP glycoconjugate vaccines generated high protein- and polysaccharide-specific antibody titers. Importantly, immunized animals receiving the AuNP-FlgL-LPS alone or as a combination demonstrated up to 100% survival and reduced lung colonization following a lethal challenge with B. pseudomallei. Together, this study provides a rational approach to vaccine design that can be adapted for other complex pathogens and provides a rationale for further preclinical testing of AuNP glycoconjugate in animal models of infection.

KW - Burkholderia pseudomallei

KW - Melioidosis

KW - Nanoglycoconjugate

KW - Nanovaccine

KW - Reverse vaccinology

UR - http://www.scopus.com/inward/record.url?scp=85036514399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036514399&partnerID=8YFLogxK

U2 - 10.1128/CVI.00206-17

DO - 10.1128/CVI.00206-17

M3 - Article

VL - 24

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 11

M1 - e00206-17

ER -